The Efficacy of Azvudine and Paxlovid in High-risk Patients With COVID-19: A Prospective Randomized Controlled Trial
Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
This is a randomized controlled clinical study on the clinical efficacy of Azvudine and
Paxlovid antivirus therapy in COVID-19 patients with high-risk. The objective is to examine
the effect of high-risk on the time for COVID-19 patients to achieve 2 continuously negative
SARS-CoV-2 nucleic acid test result, and the RT-PCR negative conversion rates in day 7.
Patients who meet inclusion criteria will be randomized into the Azvudine group (treatment
group) and Paxlovid group (control group).
Phase:
N/A
Details
Lead Sponsor:
Southeast University, China
Collaborator:
Hohhot First Hospital, Hohhot, Inner Mongolia, China